08:09 AM EST, 02/17/2026 (MT Newswires) -- Janux Therapeutics ( JANX ) said Tuesday the first participant has been dosed in a phase 1 clinical study of JANX011, a potential treatment for autoimmune diseases engineered using the company's proprietary platform.

The therapy is designed to enable a reset of the immune system through targeted depletion of CD19-expressing B cells in blood and tissue.

A single, subcutaneous dose of JANX011 showed "deep and durable" results in preclinical studies, the company said.

The current study is expected to inform dose selection and prioritization of indications in subsequent trials and development, the company said.